[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nutritional-and-metabolic-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nutritional-and-metabolic-diseases":34},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,49,91,125,147,172,199,224,251],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100054307","phase-2-metabolic-modulation-to-enhance-insulin-sensitivity-and-mitochondrial-function-in-type-1-diabetes-metmod-t1d-100054307",false,"NCT07699380","METabolic MODulation to Enhance Insulin Sensitivity and Mitochondrial Function in Type 1 Diabetes (MetMod-T1D)","MetMod-T1D","Inclusion Criteria:\n\n1. Adults ≥18 years to \\\u003C70 years of age with established T1D (duration ≥1 year)\n2. Currently on insulin therapy (multiple daily injections or insulin pump)\n3. HbA1c \\\u003C9.5%\n4. BMI 18.5-40 kg\u002Fm2\n5. On stable dose of RASB or statin, if indicated\n6. Willing and able to comply with all study procedures\n\nExclusion Criteria:\n\n1. History of pancreatic disease (including pancreatitis) or pancreatic surgery\n2. History of cardiovascular disease or stroke within the past 6 months\n3. History of heart failure per New York Heart Association criteria\n4. History of severe edema or salt restriction requirement\n5. Biliary disease or pathologies that may alter enterohepatic circulation of bile acids\n6. Estimated glomerular filtration rate (eGFR) \\\u003C60 mL\u002Fmin\u002F1.73m²\n7. Liver disease (ALT\u002FAST \\>3x upper limit of normal \\[ULN\\])\n8. Pregnancy, breastfeeding, or planning pregnancy during the study period\n9. Known hypersensitivity to study drug components\n10. Abnormal baseline ECG\n11. Use of off label medications that affect insulin sensitivity within the past 1 month (e.g., metformin, GLP-1RA, SGLT2i, pioglitazone)\n12. Chronic use of anticoagulants\n13. Use of bile acid sequestering agents, inhibitors of bile acid transporters, bile acid derivatives, aluminum-based antacids, probenecid, pan-HDAC inhibitors, phase 2 metabolizing enzymes (e.g., uridine diphosphate glucuronosyl transferases), phase 1 metabolizing enzymes other than cytochrome P450 enzymes (CYPs), and OATP1B3\n14. Use of substrates of CYP1A2, CYP2C8, CYP2B6, CYP3A4, Organic Anion transporter 1, P-glycoprotein, and Breast Cancer Resistance Protein\n15. History of severe hypoglycemia requiring assistance within the past 3 months\n16. History of diabetic ketoacidosis (DKA) within the past 3 months\n17. Personal or family history of breast cancer or ovarian cancer\n18. Current participation in another clinical trial\n19. Any condition(s) found by the study team and confirmed with the Investigator that make it unsafe to participate","ALL","18 Years","69 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The study is a randomized, double-blind, parallel-group clinical trial to examine the effects of 24 weeks of oral AMX0035 (sodium phenylbutyrate + taurursodiol) versus placebo in 60 adults with Type 1 Diabetes (T1D) (n=30 per arm). Enrollment will be distributed equally between the University of Washington and Amsterdam University Medical Center\u002FDiabetes Center Amsterdam. Participants will be recruited through diabetes research registries, local T1D clinics, and community outreach.",[27,28,29,30,31,32,33,34,35],"Type 1 Diabetes (T1D)","Metabolic Diseases","Glucose Metabolism Disorders","Endocrine System Diseases","Autoimmune Diseases","Immune System Diseases","Diabetes Melletus, Type 1","Nutritional and Metabolic Diseases","Combination Therapy","RECRUITING","2026-07-09",{"date":39,"type":40},"2026-07-13","ACTUAL",{"date":42,"type":21},"2026-06",{"date":44,"type":21},"2029-12",{"name":46,"class":47},"University of Washington","OTHER",2,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":62,"conditions":63,"keywords":77,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":90},"100637347","phase-3-a-study-of-orforglipron-ly3502970-in-participants-with-type-2-diabetes-who-observe-ramadan-fasting-100637347","NCT07613307","A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting","A Phase 3b, Multicenter, Multi-Country, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Orforglipron in Adult Participants With Type 2 Diabetes Who Observe Ramadan Fasting (ACHIEVE-RAM)","ACHIEVE-RAM","Inclusion Criteria:\n\n* Have a clinical diagnosis of T2D based on the World Health Organization (WHO) classification or other locally applicable diagnostic standards.\n* Have an HbA1c value of at least 7.0% (53 millimoles per mole (mmol\u002Fmol)) to less than 9.5% (91 mmol\u002Fmol) at screening.\n* Intend to be compliant with the fast during the Ramadan period.\n* Have had stable body weight self-reported change of 5 kilograms (kg) or lower during the 90 days prior to screening.\n* Have body mass index (BMI) of 25 kilograms per meter square (kg\u002Fm2) or higher at screening.\n\nExclusion Criteria:\n\n* Have any form of diabetes other than T2D, including type 1 diabetes (T1D), gestational diabetes, latent autoimmune diabetes, maturity-onset diabetes of the young, and medication-induced diabetes\n* Have a family (first-degree relative) or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.\n* Have a history of chronic or acute pancreatitis any time prior to screening\n* Have evidence of a significant, uncontrolled endocrine abnormality, for example, thyrotoxic or adrenal crises, in the opinion of the investigator\n* Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years.\n* Have a history of cholecystectomy (surgically removed gallbladder)\n* Have New York Heart Association Functional Classification IV congestive heart-failure.","65 Years",{"count":59,"type":21},130,[61],"PHASE3","The purpose of this study is to test the efficacy and safety of orforglipron in participants with T2D (type 2 diabetes) who participate in fasting during Ramadan. For each participant, the study will last up to 48 weeks with a minimum of 7 in clinic visits and 4 virtual visits.",[64,65,29,66,34,30,67,68,69,70,71,72,73,74,75,76],"Diabetes Mellitus, Type 2","Diabetes Melletus","Metabolic Disorders","Feeding Behavior","Behavior","Fasting","Glucagon-Like Peptide-1 Receptor","Glucagon-Like Peptide Receptors","Receptors, G-Protein-Coupled","Receptors, Cell Surface","Membrane Proteins","Proteins","Receptors, Peptide",[78,69],"Ramadan","NOT_YET_RECRUITING","2026-06-18",{"date":82,"type":40},"2026-06-23",{"date":84,"type":21},"2026-07",{"date":86,"type":21},"2027-05",{"name":88,"class":89},"Eli Lilly and Company","INDUSTRY",37,{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":22,"phases":101,"briefSummary":102,"conditions":103,"keywords":111,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":124},"100642828","phase-2-a-study-of-pf-08653945-and-pf-08653944-in-adults-with-overweight-or-obesity-solis-1-100642828","NCT07575932","A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1)","A PHASE 2B, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, DOSE RANGING, DOSE-FINDING, UMBRELLA STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08653945 AND PF-08653944, ALONE OR IN COMBINATION, IN ADULTS WITH OVERWEIGHT OR OBESITY (SOLIS-1)","SOLIS-1","Inclusion Criteria:\n\nEligible participants for this study include:\n\n* adults aged 18 years or older with\n* obesity (BMI of 30.0 kg\u002Fm2 to 50.0 kg\u002Fm2) or with\n* overweight (BMI of 27.0 kg\u002Fm2 to \\\u003C30.0 kg\u002Fm2) who also have at least 1 prespecified weight-related comorbidity (hypertension, dyslipidemia, cardiovascular disease, or obstructive sleep apnea), at the screening visit.\n\nExclusion Criteria:\n\nParticipants who are not eligible include those with diabetes mellitus, a body weight change of \\>5% or use of weight loss medications in the 12 weeks prior to screening, a history of or plan for surgical treatment for obesity, and those who are unable or unwilling to comply with contraceptive requirements or are pregnant or lactating.",{"count":100,"type":21},872,[24],"This study is being done to learn about the safety and effects of the study drugs, PF-08653945 and PF-08653944, when given alone or together for weight loss, compared to a placebo (a dummy drug that has no active ingredient in it).",[104,105,106,107,108,109,34,110],"Overweight","Obesity","Overweight and\u002For Obesity","Overweight or Obesity","Overnutrition","Nutrition Disorders","Body Weight",[108,109,34,110,105,104,112,113,114],"GLP-1RA","Amylin","DACRA","2026-06-09",{"date":117,"type":40},"2026-06-10",{"date":119,"type":40},"2026-05-11",{"date":121,"type":21},"2028-01-05",{"name":123,"class":89},"Pfizer",48,{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":133,"sex":16,"minAge":17,"maxAge":57,"enrollmentInfo":134,"targetDuration":4,"studyType":22,"phases":135,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":48},"100514058","blood-lipid-responses-to-diet-macronutrients-100514058","NCT05973539","Blood Lipid Responses to Diet Macronutrients","Investigating Blood Lipid Responses to Dietary Macronutrient Content","BoLD","Inclusion Criteria:\n\n* Participant is willing and able to give informed consent for participation in the study.\n* Male or Female, aged ≥18 to ≤65 years\n* Body mass index (BMI) ≥19 to ≤35 kg\u002Fm2\n* No medical condition or relevant drug therapy that is known to affect the liver, adipose tissue, or cardiac metabolism.\n* Weight stable for the previous 3 months\n\nExclusion Criteria:\n\n* Aged \\\u003C18 or \\>65 years\n* BMI \\\u003C19 or \\>35 kg\u002Fm2\n* A blood haemoglobin \\\u003C135 mg\u002FdL for men and \\\u003C120 mg\u002FdL for women\n* Donated (or lost) ≥250 mL of blood in the previous two months\n* On a weight loss diet or decreased their body weight by \\>5% in the previous 3 months\n* Currently adhering to or have consumed in the previous 3 months a diet with a notably altered macro-nutrient content (e.g. high-fat - low-carbohydrate diet)\n* Have increased their body weight by \\>5% in the previous 3 months\n* Any metabolic condition or relevant drug therapy\n* Current smoker\n* History of alcoholism or a greater than recommended alcohol intake (\\>30 g of alcohol daily for men and \\>20 g of alcohol daily for women)\n* History of albumin allergy.\n* Pregnant or nursing mothers\n* History of severe claustrophobia",true,{"count":20,"type":21},[136],"NA","The macronutrient composition of a diet (proportions of carbohydrates, fats and proteins) strongly influences the way the body stores and utilises substrates (e.g., fats and sugars), which in turn influences the risk of developing cardiometabolic diseases (e.g., coronary artery disease or insulin resistance). The optimal dietary composition to lower the risk of cardiometabolic disease is unknown.\n\nIn a randomized, parallel design, this study will investigate how the overconsumption of carbohydrates and fats affects blood lipid responses and liver metabolism in adults free from metabolic disease. By genotyping participants, the interaction between macronutrient content and an individual's genes on blood lipid responses and liver metabolism will be examined.",[34],"2026-05-06",{"date":119,"type":40},{"date":142,"type":40},"2023-02-15",{"date":144,"type":21},"2028-01",{"name":146,"class":47},"University of Oxford",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":16,"minAge":153,"maxAge":154,"enrollmentInfo":155,"targetDuration":4,"studyType":22,"phases":157,"briefSummary":158,"conditions":159,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":171},"100553196","whole-food-for-families-a-pilot-rct-of-a-dietary-guidelines-based-intervention-to-prevent-type-2-diabetes-100553196","NCT06482944","Whole Food for Families: A Pilot RCT of a Dietary Guidelines-Based Intervention to Prevent Type 2 Diabetes","Inclusion Criteria:\n\nFor this study, eligible adults will be those that:\n\n1. are 25 to 59 years of age at time of initial screen and identify as a parent to at least one child or adolescent 6-18 years;\n2. have a body mass index of between ≥23kg\u002Fm2 to \\\u003C40kg\u002Fm2;\n3. have prediabetes (based on American Diabetes Association criteria of either fasting plasma glucose of ≥100 mg\u002FdL, HgbA1c 5.7-6.4%, or 2-hour plasma glucose during 75-g oral glucose tolerance test \\[OGTT\\] 140 mg\u002FdL to 199 mg\u002FdL) with recent lab values reported within the prior 6-12 months and confirmed by an HbA1c A1cNow+ collected prior to enrollment (\\*see comment below);\n4. have no special dietary restrictions or food allergies that would prohibit consumption of a variety of foods\u002Fbeverages;\n5. are English speaking;\n6. reside in Greater Nashville Tennessee and willing to come to Vanderbilt campus and Vanderbilt University Medical Center for required study visits;\n7. are without medical conditions that would limit participation in a diet-related study (e.g., tube feeding, dysphagia, severe food allergy causing anaphylaxis);\n8. are able to participate in a 12-week dietary program that requires home preparation\u002Fcooking for meals and snacks;\n\nFor this study, eligible offspring will be those that:\n\n1. Are 6-18 years at time of initial screen;\n2. Have an index parent with prediabetes that is actively enrolled in the program;\n3. have body mass index ≥5th percentile for age and gender on standardized CDC growth curves;\n4. have no special dietary restrictions or food allergies that would prohibit consumption of a variety of foods\u002Fbeverages;\n5. have parental commitment to participate in a 12-week research study\n6. are English speaking;\n7. reside in the Greater Nashville Tennessee area and live at home with their index parent during the duration of 12- week study;\n8. are without medical conditions that would limit participation in a diet-related study (e.g., tube feeding, dysphagia, severe food allergy causing anaphylaxis);\n9. are able to participate in a 12-week dietary program that includes at least dinner and snacks provided during after-school hours;\n\nExclusion Criteria:\n\nAdult exclusion criteria include:\n\n1. Adults who's HbA1c test is outside of the HbA1c range during screening\\* (see details related to screening results)\n2. adults outside the specified age range of \\\u003C25 years or \\>59 years;\n3. adults whose body mass index is \\\u003C23kg\u002Fm2 or those with a body mass index ≥40kg\u002Fm2 as that degree of morbid obesity represents a different phenotype where dietary behavioral intervention alone may not be sufficient to achieve weight loss);\n4. receiving care by a healthcare provider (i.e., MD, NP, PA) for a complicated diagnosis of prediabetes that requires routine glycemic monitoring or frequent healthcare visits for management\u002Ftreatment;\n5. adults actively participating in any type of weight loss program (dietary or physical activity)\n6. adults with a prior history of type 2 diabetes;\n7. adults who are not English speaking or have limited English-language proficiency;\n8. adults with special dietary restrictions, food allergies, or medical conditions that prohibit participation in a diet-related study;\n9. adults with serious mental or neurologic illness that impairs the ability to consent\u002Fparticipate;\n10. women who are pregnant or nursing due to increased metabolic state requiring greater energy requirements;\n11. adults currently taking medications to treat diabetes or to promote weight loss;\n12. adults living outside Greater Nashville Tennessee or who are unwilling to travel to Vanderbilt for study visits;\n13. adults who do not otherwise meet the eligibility criteria listed in sections above as determined by pre-screen;\n\nOffspring (child\\[ren\\] and adolescent\\[s\\]) exclusion criteria include:\n\n1. children\u002Fadolescents outside the specified age range of \\\u003C6 years or \\>18 years;\n2. children\u002Fadolescents whose body mass index is \\\u003C5th percentile for age and gender on standardized CDC growth curves;\n3. children\u002Fadolescents who do not have an eligible index parent participating in the study;\n4. children who do not have parental commitment to participate consistently for 12-weeks\n5. children\u002Fadolescents who are not English speaking or have limited English-language proficiency;\n6. children\u002Fadolescents with special dietary restrictions, food allergies, or medical conditions that prohibit participation in a diet-related study;\n7. children\u002Fadolescents who display dissenting behaviors during baseline data collection;\n8. children\u002Fadolescents actively participating in any type of weight loss program (medical or lifestyle);\n9. children\u002Fadolescents who do not otherwise meet the eligibility criteria listed in sections above as determined by pre-screen;","6 Years","59 Years",{"count":156,"type":21},30,[136],"This study will address the following aims:\n\nAim 1 (primary): Conduct a pilot RCT to evaluate the feasibility, acceptability, enrollment, and retention rates of adult-child pairs after a 12-week family-centered, non-calorie restricted whole foods diet.\n\nFeasibility: ≥80% participant retention and completion of study outcome measures.\n\nAcceptability: ≥75 adult diet satisfaction via survey report and\u002For perceived diet satisfaction via focus groups. Aim 2: Conduct a pilot RCT to evaluate the preliminary effectiveness of a non-calorie restricted whole foods diet on adult HbA1c at 12 weeks and adult\u002Fchild diet quality during the 12-week intervention.\n\nAim 2a: Evaluate intervention effects on HbA1c measures in adults with prediabetes.\n\nHypothesis 2a: Adults randomized to the treatment group will have lower HbA1c measures at 12 weeks than those in the control group.\n\nAim 2b: Evaluate intervention effects on the diet quality (via the 2020 HEI) of adults and children. Hypothesis 2b: Adults and children randomized to the treatment group will have a higher diet quality score during the 12-week intervention period compared to adults and children in the control group.\n\nAim 3: Conduct family focus groups to understand how SDOH and individual\u002Ffamily needs and preferences may be perceived barriers or facilitators of diet adherence.",[160,161,34],"PreDiabetes","Diet, Healthy","2026-03-05",{"date":164,"type":40},"2026-03-06",{"date":166,"type":40},"2025-10-13",{"date":168,"type":21},"2027-06-30",{"name":170,"class":47},"Vanderbilt University",1,{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":16,"minAge":178,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":22,"phases":181,"briefSummary":182,"conditions":183,"keywords":184,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":171},"100595764","the-faibago-study---long-term-weight-reduction-via-low-threshold-intervention-100595764","NCT07036692","The FaibaGo Study - Long-Term Weight Reduction Via Low-Threshold Intervention","Inclusion Criteria:\n\n* Informed Consent (IC) according to ICH\u002FGCP regulations prior to any study-specific procedures\n* Adults aged ≥ 25 years\n* Overweight as determined by a Body Mass Index \\> 25 kg\u002Fm2\n* Metabolic risk factor: at least one of the following criteria:\n\n  i. HbA1c ≥ 5.7% ii. Elevated liver enzymes (ALAT, ASAT, Gamma-Glutamyltransferase (gGT) at least one above normal range of the assay used in the respective laboratory) iii. LDL-cholesterol \\> 3.0 mmol\u002Fl iv. Triglycerides \\> 1.7 mmol\u002Fl\n* Ability and willingness to follow the study protocol (e.g., cognitive capacity for compliance, gum chewing, faecal sample collection)\n* Access to a scale to self-report weight\n* Access and willing to use an electronic device (e.g., mobile phone, computer or tablet)\n* Laboratory assessments of blood parameters were performed within a reasonable timeframe prior to the eligibility assessment, as determined by the PI.\n\nExclusion Criteria:\n\n* Systemic antibiotic use within the last 2 months\n* History of bariatric surgery\n* Initiation or dose adjustment of pharmaceutical treatment for dyslipidemia or hyperglycemia within the last 3 months or during the study (e.g., metformin, statins, SGLT2 inhibitors)\n* Use of prebiotic or probiotic supplementation (duration \\>1 month) within the last 6 weeks (at PI's discretion, based on medication summary of TP)\n* Medical weight management treatments within the last year (e.g., Glucagon-Like Peptide-1 (GLP-1) agonists)\n* Recent (\\\u003C1 month) dose adjustment, initiation or termination of proton pump inhibitors use (e.g., pantoprazole, omeprazole)\n* Professionally supervised intensive (\\>6 months of ongoing supervision) weight management treatments (e.g., structured nutrition counselling) within the last year (at the PI's discretion)\n* Diagnosis of Type 1 or Type 2 diabetes requiring bolus insulin therapy or frequent dose adjustments in base line insulin\n* Regular alcohol consumption exceeding two (women) or three (men) standard units (10 g of pure alcohol) per day\n* Consumption of more than one nicotine product (e.g., (e-)cigarette, gum) per month\n* Regular drug abuse (once per week over the past 4 months)\n* Any stage of known pregnancy or lactation period (self-reported)\n* Active cancer or recent cancer treatment (within the last 4 months)\n* Chronic, active inflammatory diseases (e.g., inflammatory bowel disease, rheumatoid arthritis)\n* Severe gastrointestinal disorders (e.g., celiac disease, short bowel syndrome, gastroparesis)\n* Known eating disorder (medically diagnosed)\n* Participation in another investigation with an investigational drug within the 30 days preceding randomisation\n* Dependency from the Sponsor-Investigator\n* Last visit with TP \\> 22 days prior to eligibility assessment","25 Years",{"count":180,"type":21},120,[136],"The main aim of this study is to assess the effect of a chewing gum containing galactooligosaccharides (GOS) on the body mass index (BMI), the metabolism and the oral and intestinal microbiomes in a population of overweight adults.",[34,104],[104,185,186,187,188,189],"Chewing gum","Galactooligosaccharides","GOS (Galactooligosaccharides)","Oral microbiome","Intestinal microbiome","2025-11-17",{"date":192,"type":40},"2025-11-21",{"date":194,"type":40},"2025-10-09",{"date":196,"type":21},"2026-12",{"name":198,"class":47},"University of Bern",{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":16,"minAge":206,"maxAge":207,"enrollmentInfo":208,"targetDuration":4,"studyType":210,"phases":4,"briefSummary":211,"conditions":212,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":171},"100515996","influence-of-glucose-on-metabolism-and-clinical-symptoms-of-patients-with-parkinsons-disease-100515996","NCT05998772","Influence of Glucose on Metabolism and Clinical Symptoms of Patients With Parkinson's Disease","PaGlu","Inclusion Criteria:\n\n* Diagnosis of Parkinson's Disease, stage Hoehn \\& Yahr 1.5-3\n* Ability to pause antiparkinsonian medication in the morning without relevant impairment\n* Capacity to give consent (determined in doubt by two independent neurologists, MOCA ≥18) and written informed consent.\n* Patients are between 50 and 80 years of age, with exceptions for a maximum of 5 additional patients enrolled per group\n* For stratification into patients with and without sweet craving, a 3-day dietary protocol should be completed once by the patients\n* Group I: increased hunger for sweets.\n* Group II: no increased hunger for sweets.\n\nFor the stratification into patients with and without increased hunger for sweets, participants are asked to answer the following questions:\n\n1. Do you have sudden attacks of cravings for sweets?\n2. Would you say that your consumption of sweet food has increased in recent years?\n3. Would you describe your consumption of sugary food as increased or excessive?\n\nIf one of the questions is answered with yes, participants will be assigned to group I, if all questions are answered with no, participants will be assigned to group II.\n\nExclusion Criteria:\n\n* Other significant neurological diseases primarily affecting the central nervous system (e.g., multiple sclerosis)\n* Diagnosis of diabetes mellitus or prediabetes\n* Use of medications that affect glucose metabolism, such as antidiabetics, glucocorticoids, ciclosporin, tacrolimus, sirolimus, beta-blockers, thiazide diuretics, beta-2 adrenoreceptor agonists, theophylline, Clozapine, olanzapine, paliperidone, quetiapine, risperidone, tricyclic antidepressants, mirtazapine, mianserin, carbamazepine, gabapentin, pregabalin, valproic acid, lithium, antiretroviral drugs, statins\n* cardiac or brain pacemakers","50 Years","80 Years",{"count":209,"type":21},50,"OBSERVATIONAL","Many patients with Parkinson's Disease (PD) report an increased consumption of fast-acting sugars. This tendency to consume sweet, high-sugar foods occurs in some patients even before the onset of cardinal motor symptoms. Some recent studies have demonstrated that PD patients have an increased consumption of fast-acting carbohydrates compared to healthy controls. However, the reason for this change in eating behavior has not yet been adequately explained. It is discussed that the increased sugar intake leads to an increased dopamine release in the brain via an increase in insulin and thus to an improvement in clinical symptoms. This study investigates the influence of fast-acting carbohydrates on insulin and glucose blood levels as well as motor and non-motor symptoms in patients with PD using an oral glucose tolerance test and a placebo oral glucose tolerance test in a crossover design.",[213,34,214],"Parkinson Disease","Sugar Intake","2025-09-16",{"date":217,"type":40},"2025-09-22",{"date":219,"type":40},"2023-09-01",{"date":221,"type":21},"2025-12",{"name":223,"class":47},"University Hospital Schleswig-Holstein",{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":228,"acronym":229,"eligibilityCriteria":230,"healthyVolunteers":133,"sex":16,"minAge":17,"maxAge":231,"enrollmentInfo":232,"targetDuration":4,"studyType":22,"phases":234,"briefSummary":235,"conditions":236,"keywords":238,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":171},"100494879","postprandial-glucose-levels-gut-microbiota-and-supplementation-with-functional-foods-in-adults-100494879","NCT05723913","Postprandial Glucose Levels, Gut Microbiota and Supplementation With Functional Foods in Adults","PPGR","Inclusion Criteria:\n\n* Male and female\n* Adults between 18 and 60 years of age.\n* The signing of the informed consent.\n\nExclusion Criteria:\n\n* Patients with any type of diabetes.\n* Patients with high blood pressure.\n* Patients with acquired diseases secondarily producing obesity and diabetes.\n* Patients who have suffered a cardiovascular event.\n* Patients with gastrointestinal diseases.\n* Weight loss \\> 3 kg in the last 3 months.\n* Catabolic diseases such as cancer and acquired immunodeficiency syndrome.\n* Pregnancy status.\n* Drug treatment:\n\n  * Antihypertensive drugs or treatment (thiacycline, loop or potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, alpha blockers, calcium antagonists, beta blockers).\n  * Treatment with hypoglycemic agents (sulfonylureas, biguanides, incretins) or insulin and antidiabetic drugs.\n  * Treatment with statins, fibrates or other drugs to control dyslipidemia.\n  * Use of antibiotics in the three months prior to the study.\n  * Use of steroid drugs, chemotherapy, immunosuppressants, or radiation therapy.\n  * Anorexigenic or that accelerate weight loss such as sibutramine or orlistat.\n  * Supplements with any of the functional foods used in the study.\n  * Probiotic, prebiotic or symbiotic supplements.","60 Years",{"count":233,"type":21},200,[136],"This is a clinical study with participants over 18 years of age that meet the selection criteria. This will be 42-day study divided into three phases of 14 days each: 14 days without intervention, 14 days with intervention with functional foods and 14 days without intervention again. With the objective of assess the changes in the postprandial glycemic responses through the gut microbiota and urine metabolites.",[237,34],"Healthy",[239,240,241],"Postprandial glucose responses","Gut microbiota","Functional foods","2025-06-13",{"date":244,"type":40},"2025-06-18",{"date":246,"type":40},"2023-06-07",{"date":248,"type":21},"2026-10-01",{"name":250,"class":47},"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran",{"id":252,"slug":253,"hasResults":11,"nctId":254,"briefTitle":255,"officialTitle":255,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":257,"targetDuration":4,"studyType":22,"phases":258,"briefSummary":259,"conditions":260,"keywords":262,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":4},"100436941","comparison-of-atherogenic-risk-factors-and-efficacy-of-nutritional-treatment-among-adult-phenylketonuria-patients-100436941","NCT04969809","Comparison of Atherogenic Risk Factors and Efficacy of Nutritional Treatment Among Adult Phenylketonuria Patients","Inclusion Criteria:\n\n* The study will include subjects over the age of 18 who have PKU or hyperphenylalaninemia and are expected to have dietary treatment according to expert recommendations. A prerequisite for entering the investigation will be a signed consent to participate in the investigation and the ability of the participant to have a good understanding of the content of the research and to fully participate in the interventional dietary process.\n\nExclusion Criteria:\n\n* The investigators will not include adult patients who do not manage their diet on their own and need caregivers due to limited cognitive abilities (patients with late-diagnosed disease and neurological consequences of the disease) or who do not want to sign an informed consent.",{"count":209,"type":21},[136],"Phenylketonuria is a rare metabolic disease that results from the absence or near-absence activity of the enzyme phenylalanine hydroxylase, which metabolizes the amino acid phenylalanine to tyrosine in the body. Accumulation of phenylalanine in the brain causes brain damage that leads to mental retardation, neurological complications, and movement disorders.\n\nThe study is inherited autosomal recessively. The basis of treatment is a low-protein diet with dietary supplements of aminoxlin without phenylalanine and with appropriate substitutes for micro and macronutrients needed for different ages. A low-protein diet regulates the level of phenylalanine in the blood. This is especially important in childhood.\n\nIn the study, which will basically consist of theoretical, experimental and numerical work, the investigators will limit to a specific population, i.e. to adult patients with phenylketonuria. The research is intended to prove the hypothesis that with proper nutritional treatment of phenylketonuria in adulthood, we can have a positive effect on the patient's well-being, better blood results and improved lifestyle.\n\nThe investigators intend to test this hypothesis by implementing a complex, multidisciplinary project that will include a comprehensive treatment of adult PKU patients. This will be based on a multidisciplinary approach with the inclusion of medical and nutritional treatment. As part of the project, the investigators, among other things, create questionnaires and analyze food diaries related to the mentioned areas.\n\nUsing various statistical techniques, the investigators analyze the impact of individual factors on the success of achieving the objectives of the proposed study. The original contribution to science will be the nutritional treatment of adult patients with phenylketonuria in Slovenia and the consequent reduction of health complications in adulthood of patients with phenylketonuria.",[261,34],"Phenylketonurias",[263,264,265,266],"adult phenylketonuria","nutrition therapy","cardiovascular diseases","nutrition and metabolic diseases","2021-07-09",{"date":269,"type":40},"2021-07-21",{"date":271,"type":21},"2021-09-01",{"date":273,"type":21},"2026-09-01",{"name":275,"class":47},"University Medical Centre Ljubljana"]